Replies to post #179580 on Biotech Values

[linhdtu]

The problem is that there is nobody else but abbvie. My thesis is that it is too hard for a 3rd party(beyond abbvie) to come in and untangle the legalities.

So imo if abbvie does not bid, there is probably no one else.

[caravon]

Considering what MRK paid for IDIX's nukes as well as what seems like a real interest by NVS in advancing ENTAs compound, I would like to think $1.5b would be the minimum someone would have to pay.

Why $1.5b? Why not 0.5B, $3B or $5B?

Remember that no Big Pharma will touch a product with a potential sale below $300M.